CD4 and lung carcinoma: We found that the T4 treatment significantly impaired the cell viability of A549 and A549/DDP lung cancer cells, and the cells that received the 3-MA pretreatment plus the subsequent T4 treatment revealed no significant differences in the cell viability, except for those exposed to 200 nM and 400 nM of T4 for 24-48 h.